Novo-nordisk a/s's parent company, Novo Holdings, has acquired the pharmaceutical manufacturer catalent (CTLT.US) in a trade valued at 16.5 billion dollars.
Regulatory institutions stated that the EU unconditionally approved the trade after finding that the agreement would not raise competition concerns in europe.
